Objective This study aimed to evaluate the efficacy and safety of topical cyclosporine in the treatment of oral lichen planus (OLP) and to provide reference for clinicians. Methods Databases, such as Pubmed, Embase, The Cochrane Library, Web of Science, CNKI, WanFang Data, and VIP, were searched. The System for Information on Grey Li-terature in Europe (SIGLE) and ClinicalTrials websites were searched online to collect randomized controlled trials (RCTs) of cyclosporine for OLP from the establishment of the database to March 25, 2023. Two reviewers independently evalua-ted the study quality and extracted data, and meta-analysis was performed using RevMan (version 5.4) and STATA (version 14.0) software. Results A total of seven RCT studies on cyclosporine in the treatment of OLP were included, including 317 patients. Among them, six compared cyclosporine with corticosteroid, and one compared cyclosporine with placebo. Meta-analysis results showed no statistically significant difference in clinical effectiveness between the cyclosporine and corticosteroid groups [risk ratio (RR)=0.87, 95% confidence interval (CI): 0.67-1.14, P=0.32]. After 4 weeks of treatment, no statistically significant difference was observed in the improvement of pain scores between the cyclosporine and corticosteroid groups (standardized mean difference=-0.23, 95%CI: -0.54-0.07, P=0.13). No statistically significant difference was found in the incidence of adverse reactions between the cyclosporine and corticosteroid groups (RR=0.71, 95%CI: 0.18-2.79, P=0.62). Conclusion Current evidence shows that cyclosporine has no advantage over corticosteroid in terms of clinical efficacy, improvement in pain scores, and safety. More high-quality studies are required to verify the above conclusion due to limitations in the quantity and quality of included studies.